X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 138-144

  Lamas, Maria J ^a   Duran, Goretti ^a   Gomez, Antonio ^a   Balboa, Emilia ^b   Anido, Urbano ^a   Bernardez, Beatriz ^a   Rana Diez, Pablo ^b   Lopez, Rafael ^a   Carracedo, Angel ^c   Barros, Francisco ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Fundacion Publica Galega de Medicina Xenomica   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Chemoradiotherapy; Polymorphisms; Rectal cancer; Thymidylate synthase; X ray cross complementing group 1; XRCC1

Indexed keywords

CHEMORADIOTHERAPY; RECTAL CANCER; THYMIDYLATE SYNTHASE; X-RAY CROSS-COMPLEMENTING GROUP 1; XRCC1;

GENES; PATIENT TREATMENT; POLYMORPHISM; SURVEYS; TUMORS; X RAYS;

DISEASES;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DPYD PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; PHARMACOLOGICAL BIOMARKER; THYMIDYLATE SYNTHASE; TYMS PROTEIN; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION INJURY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CARCINOMA; RECTUM RESECTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENES, ERBB-1; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM GRADING; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; REMISSION INDUCTION; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 83955162971     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.053     Document Type: Article

References (31)

1. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
2. J.F. Bosset, L. Collette, and G. Calais Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 2006 1114 1123
3. M.S. Roh, L.H. Colangelo, and M.J. O'Connell Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03 J Clin Oncol 27 2009 5124 5130
4. B. Iacopetta, F. Grieu, and D. Joseph A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil Br J Cancer 85 2001 827 830
5. E. Marcuello, A. Atles, and E. del Rio Single nucleotide polymorphism in the 5 tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients Int J Cancer 112 2004 733 737
6. H. Lenz, W. Zhang, and S. Zhahedy A 6 base-pair deletion in the 3′UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: A possible candidate gene for colorectal cancer risk [Abstract] Proc Am Assoc Cancer Res 43 2002 660
7. M. Raida, W. Schwabe, and P. Hausler Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls Clin Cancer Res 7 2001 2832 2839
8. M.C. Etienne, J.L. Formento, and M. Chazal Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients Pharmacogen Genom 14 2004 785 792
9. F. Graziano, A. Ruzzo, and F. Loupakis Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer J Clin Oncol 26 2008 1427 1434
10. E.J. Duell, J.K. Wiencke, and T.J. Cheng Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells Carcinogenesis 21 2000 965 971
11. A.M. Mandard, F. Dalibard, and J.C. Mandard Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations Cancer 73 1994 2680 2686
12. M.V. Mandola, J. Stoehlmacher, and S. Muller-Weeks A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity Cancer Res 63 2003 2898 2904
13. M.V. Mandola, J. Stoehlmacher, and W. Zhang A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels Pharmacogenet Genom 14 2004 319 327
14. F. Gebhardt, K.S. Zanker, and B. Brandt Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1 J Biologic Chem 274 1999 13176 13180
15. J. Suarez, R. Vera, and E. Balen Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer Colorectal Dis 10 2008 563 568
16. L. Losi, G. Luppi, and M. Gavioli Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy Int J Colorectal Dis 21 2006 645 651
17. F.V. Negri, N. Campanini, and R. Camisa Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy Br J Cancer 98 2008 143 147
18. E. Villafranca, Y. Okruzhnov, and M.A. Dominguez Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer J Clin Oncol 19 2001 1779 1786
19. V. Moreno, F. Gemignani, and S. Landi Polymorphisms in genes of nucleotide and base excision repair: Risk and prognosis of colorectal cancer Clin Cancer Res 12 2006 2101 2108
20. Y. Huang, L. Li, and L. Yu XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: A meta-analysis Mutagenesis 24 2009 331 339
21. X. Wu, J. Gu, and T.T. Wu Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer J Clin Oncol 24 2006 3789 3798
22. J. Chang-Claude, O. Popanda, and X.L. Tan Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients Clin Cancer Res 11 2005 4802 4809
23. E. Cecchin, M. Agostini, and S. Pucciarelli Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy Pharmacogenomics J 2010 Apr.6.
24. H.H. Ezzeldin, A.M. Lee, and L.K. Mattison Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients Clin Cancer Res 11 2005 8699 8705
25. S. Terrazzino, M. Agostini, and S. Pucciarelli A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation Pharmacogen Genom 16 2006 817 824
26. W. Zhang, O.A. Press, and C.A. Haiman Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer J Clin Oncol 25 2007 3726 3731
27. L. Pare, J. Salazar, and E. del Rio Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females J Clin Oncol 26 2008 3468
28. L. Ke, A. Kian, and M. Luka The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 2003 246 254
29. B. Federica, B. Carmelo, and L. Luisa Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 2007 1455 1461
30. G.S. Karen-Lise, N.N. Jens, and L. Jan Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region Int J Radiat Oncol Biol Phys 66 2006 500 504
31. S.R. McWhinney, and H.L. McLeod Using germline genotype in cancer pharmacogenetic studies Pharmacogenomics 10 2009 489 493